Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Feb 20;71(7):752-763.
doi: 10.1016/j.jacc.2017.12.010.

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality

Vallerie V McLaughlin  1 , Marius M Hoeper  2 , Richard N Channick  3 , Kelly M Chin  4 , Marion Delcroix  5 , Sean Gaine  6 , Hossein-Ardeschir Ghofrani  7 , Pavel Jansa  8 , Irene M Lang  9 , Sanjay Mehta  10 , Tomás Pulido  11 , B K S Sastry  12 , Gérald Simonneau  13 , Olivier Sitbon  13 , Rogério Souza  14 , Adam Torbicki  15 , Victor F Tapson  16 , Loïc Perchenet  17 , Ralph Preiss  17 , Pierre Verweij  17 , Lewis J Rubin  18 , Nazzareno Galiè  19
Affiliations
Free article
Clinical Trial

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality

Vallerie V McLaughlin et al. J Am Coll Cardiol. .
Free article

Abstract

Background: Registry data suggest that disease progression in pulmonary arterial hypertension (PAH) is indicative of poor prognosis. However, the prognostic relevance of PAH-related morbidity has not been formally evaluated in randomized controlled trials.

Objectives: The purpose of these analyses was to assess the impact of morbidity events on the risk of subsequent mortality using the landmark method and data from the SERAPHIN and GRIPHON studies.

Methods: For each study, the risk of all-cause death up to the end of the study was assessed from the landmark time point (months 3, 6, and 12) according to whether a patient had experienced a primary endpoint morbidity event before the landmark. Each analysis was conducted using data from all patients who were available for survival follow-up at the landmark.

Results: In the SERAPHIN study, on the basis of the 3-month landmark time point, patients who experienced a morbidity event before month 3 had an increased risk of death compared with patients who did not (hazard ratio [HR]: 3.39; 95% confidence interval [CI]: 1.94 to 5.92). In the GRIPHON study, on the basis of the 3-month landmark time point, there was also an increased risk with a HR of 4.48; (95% CI: 2.98 to 6.73). Analyses based on 6-month and 12-month landmarks also showed increased risk in patients who experienced morbidity events, albeit with a reduced HR.

Conclusions: These results demonstrate the prognostic relevance of PAH-related morbidity as defined in the SERAPHIN and GRIPHON studies, highlighting the importance of preventing disease progression in patients with PAH and supporting the clinical relevance of SERAPHIN and GRIPHON morbidity events. (Study of Macitentan [ACT-064992] on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension [SERAPHIN]; NCT00660179; Selexipag [ACT-293987] in Pulmonary Arterial Hypertension [GRIPHON]; NCT01106014).

Keywords: GRIPHON; SERAPHIN; disease progression; landmark analysis; survival.

PubMed Disclaimer

Comment in

Publication types

Associated data

LinkOut - more resources